|
ALNY | Alnylam Pharmaceuticals, Inc. |
|
|
ALNY | Alnylam Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.02 |
| Leverage | 84.11% |
| Market Cap | $ 38.5B |
| PE | 124.56 |
| Dividend Yield | 0.00% |
| Profit | $ 308.8m |
| Margin | 8.35% |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.